While PD-1 antibodies act directly on T cells and PD-L1 antibodies primarily block tumor- and APC-derived ligand, both generate similar functional outcomes in EMT6-based immunotherapy studies, supporting the translatability of our simulation findings. The gene discussed is PDCD1; the disease is neoplasm.